← Back to Home

Triglycerides Fall 60% After a Single Infusion: CTX310 Gene-Editing Therapy Reports Preliminary Results in 10 People

CTX310 produced substantial reductions in a small trial involving people with severe hypertriglyceridemia, but whether the effects can last for years and reduce pancreatitis or cardiovascular events remains to be answered in larger studies.

By SURL BioNews

For patients with severe hypertriglyceridemia, elevated blood lipid levels involve more than laboratory numbers; they also carry health risks such as acute pancreatitis. An early trial involving just 10 adults is attempting to change this situation with a single gene-editing treatment: after one intravenous infusion of CTX310, participants’ triglycerides fell by an average of approximately 63% at day 30. This is a substantial change in a biomarker, but proving that it can prevent disease remains some way off.

CRISPR Therapeutics announced these Phase 1b data on November 9, with Ashish Sarraju, a cardiologist at Cleveland Clinic, presenting the findings at the 2026 American Heart Association Scientific Sessions. The company funded the study, which used an open-label design without a control group. Participants had a median age of 56.5 years, and all had diabetes. Their median pretreatment triglyceride level was 1,067.7 mg/dL, and 3 had a history of pancreatitis.

CTX310 targets the liver. It uses lipid nanoparticles to deliver CRISPR-Cas9 editing tools, aiming to inactivate the ANGPTL3 gene in liver cells and reduce production of the corresponding protein. ANGPTL3 helps regulate lipid metabolism. The strategy seeks to achieve long-term lipid lowering through a lasting genetic change, but follow-up data are still needed to establish whether a single dose can sustain the effect for years.

Detailed data published by Cleveland Clinic’s Consult QD showed an average triglyceride reduction of 62.8% at day 30, with individual reductions ranging from 28.2% to 84.6%, indicating variation in the degree of response. Blood ANGPTL3 levels fell by an average of 65.3%, while non-high-density lipoprotein cholesterol also fell by approximately 51%. These results support that the therapy has affected the intended lipid metabolism pathway, but they cannot yet be translated directly into a quantified reduction in heart attack or stroke risk.

Regarding safety, 4 participants experienced adverse events considered related to treatment; none were Grade 3 or higher, and no treatment-related serious adverse events were reported. The company also noted that one participant experienced a Grade 2 infusion reaction and completed dosing after the symptoms resolved. These observations provide preliminary indications of tolerability, but a sample of 10 people remains insufficient to rule out rare or later-emerging risks.

At the data cutoff, all participants had been followed for at least 30 days, and 7 had been followed for approximately 90 days or longer. The company said reductions in ANGPTL3 and triglycerides were sustained in those who had reached 90 days of follow-up. However, the observation period for this group of patients with severe hypertriglyceridemia remains short, and the lack of a control group also limits researchers’ ability to distinguish treatment effects from natural fluctuations and other contributing factors.

Although no acute pancreatitis was reported during the trial, this does not establish that CTX310 has a preventive effect. The next key step is to confirm in larger studies how long the reductions last, which patients are most likely to benefit, and the long-term safety of permanent genetic changes. For this investigational therapy, there is an initial signal that it can lower blood lipid levels; whether it can further reduce disease and hospitalization is the central test of its clinical value.

References

  1. CRISPR Therapeutics / GlobeNewswire
  2. Cleveland Clinic
  3. Cleveland Clinic Consult QD